Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 21, 2016 10:15:07 GMT -5
finance.yahoo.com/q?s=JUNOJUno? Hopefully who ever that is behind so called receptor should start buying up the float if they had the $$
|
|
|
Post by nuklerfizzacist on Jan 21, 2016 10:16:04 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-) right, it's slow roller up the third base line and we are seeing if Mannkind is fast enough to run to first before the third baseman can bare hand it and throw Mannkind out. TBD. Who's on third?
|
|
|
Post by Jstokcton on Jan 21, 2016 10:16:20 GMT -5
Should there a SEC document to follow?
|
|
|
Post by stevil on Jan 21, 2016 10:17:18 GMT -5
For the sake of the prior baseball analogies that were posted here; no it's not the homerun many here are yearning for but I'll take this sweet little single to start the rally.... P.S. Stevil...depends on what the ~10% is based off of ...right? :-) as an optimist I'm thinking it must be 5-10 percent of more than you may be thinking. ..just my guess. ;-) Let's throw numbers out so people can see what we're talking about. I don't know how generous you want to be regarding future sales, but at around 10-15% sales royalties, (single digit to low double-digit) even at $1billion/year, we only get $100-150 million/year. That's roughly our current burn rate. I don't know about you, but I'm not nearly that generous in my estimates. It sounds like we have 3 drugs in the partnership, so maybe eventually they can all reach that number combined, but just to give you an idea, these were the top 200 drugs in 2010. If you want to assume these drugs will be in the top 200, they will net us at least $150mil/year x 3= 450 mil. So I think an average of 333 mil (x 3 to reach 1 bil) is quite generous as that would place them at an average of top 100 drugs. Can it happen? Sure. Will it? TBD. So we're not going to be able to develop the company further with R&D, not be able to hire new employees, not be able to pay a new CEO, although if Matt pulls this off we probably don't need one. But hopefully you get my point. This is merely a tourniquet right now to keep us from hemorrhaging out. This will not save the company by itself. We need more, and likely much better if we want this company to survive. From the comments, it sounds like Matt is still counting on Afrezza to become what we all hoped it would and that's what we're banking on. Keep the ship afloat long enough until Afrezza catches traction. I don't see how this deal does that for us in the short term, but I guess we need to take what we can get right now just to try. Top 200 drugs of 2010 www.drugs.com/top200.html
|
|
|
Post by dreamboatcruise on Jan 21, 2016 10:17:38 GMT -5
That's the crux - it's a start, and we needed to start somewhere. Right now I'll take any positive news and trust that there will be more collaborations to follow. One thing to keep in mind is that this deal seems to encompass EVERYTHING Mannkind is working on and not just one indication. While it would be nice to know who is behind Receptor, we might just be seeing the tip of a very big iceberg ( a good kind and not the kind that sunk the Titanic.) Like every other snippet of news we've received over the years that hid some magical pot of gold that never materialized? There's no iceberg other than the insolvency one were headed towards. There is no magic associated with this deal. Hard to judge regarding how helpful because we know nothing about the prospects of getting any of the milestones when we need them.
|
|
ssaq
Newbie
Posts: 13
|
Post by ssaq on Jan 21, 2016 10:18:31 GMT -5
What's interpretation on this bit?
"MannKind will also transfer manufacturing technology to the licensee"
Is this a transfer of TS IP? That doesn't sit well for nothing upfront + possible $100m down the road + possible ~10% sales down the road
Can it be viewed as a spinoff of TS?
|
|
|
Post by stevil on Jan 21, 2016 10:21:39 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. That would be incredibly disappointing if true. Matt did not seem to elude to that being a possibility at all. I know businessmen aren't known for their ethics, but it would be against the tone he set at JPM conference. It's my belief that he wants to keep the company public and knows that it's in the best interest of the company to do so if we can get out of the funk we're currently in. Once we get momentum, our SP will not get hammered by shorts.
|
|
|
Post by nemzter on Jan 21, 2016 10:22:25 GMT -5
Website was created 11 days ago.
Domain Name: RECEPTORLIFE.COM Registrar: ENOM, INC. Sponsoring Registrar IANA ID: 48 Whois Server: whois.enom.com Referral URL: www.enom.com Name Server: DNS1.REGISTRAR-SERVERS.COM Name Server: DNS2.REGISTRAR-SERVERS.COM Name Server: DNS3.REGISTRAR-SERVERS.COM Name Server: DNS4.REGISTRAR-SERVERS.COM Name Server: DNS5.REGISTRAR-SERVERS.COM Status: clientTransferProhibited www.icann.org/epp#clientTransferProhibited Updated Date: 10-jan-2016 Creation Date: 10-jan-2016 Expiration Date: 10-jan-2017
Goes to show that this announcement is a complete joke. Same managment team, same results.
|
|
|
Post by dreamboatcruise on Jan 21, 2016 10:22:35 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. Yes, because as we've seen in the past every deal MNKD does has a secret plan to buy them out for billions. It must be getting so confusing with all these companies behind the scenes now fighting over their rights to give us shareholders billions. Stop it! Can we please have a wild buy out speculation free zone here at Proboards. There is ZERO reason to believe there is anything beyond what was announced.
|
|
|
Post by mnholdem on Jan 21, 2016 10:25:03 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. good points. now that this is out of the way, the next fire to put out is how Mannkind can raise much needed cash unless Receptor Life is part of a plan to take MNKD private. Why not read the MannKind 2016 Blueprint Summary (posted above)? It's covered there: "Generate immediate cash and increase volume by rapid expansion into selected international jurisdictions."
Can I hear an "Israel - amen, brother!" Saudi Arabia? Others include any country that basically rubber stamps FDA-approved drugs.
Seriously, are shareholders, who have been complaining for years about lack of transparency, ignoring Matt Pfeffer (out of habit) now that MannKind's new CEO is providing guidance?
|
|
|
Post by mindovermatter on Jan 21, 2016 10:26:07 GMT -5
One thing to keep in mind is that this deal seems to encompass EVERYTHING Mannkind is working on and not just one indication. While it would be nice to know who is behind Receptor, we might just be seeing the tip of a very big iceberg ( a good kind and not the kind that sunk the Titanic.) Like every other snippet of news we've received over the years that hid some magical pot of gold that never materialized? There's no iceberg other than the insolvency one were headed towards. There is no magic associated with this deal. Hard to judge regarding how helpful because we know nothing about the prospects of getting any of the milestones when we need them. I hear ya. It is why I used the workd MIGHT. In no way am I saying this is a slam dunk deal.
|
|
|
Post by suebeeee1 on Jan 21, 2016 10:26:08 GMT -5
What's interpretation on this bit? "MannKind will also transfer manufacturing technology to the licensee" Is this a transfer of TS IP? That doesn't sit well for nothing upfront + possible $100m down the road + possible ~10% sales down the road Can it be viewed as a spinoff of TS? It wouldn't surprise me that we are spinning of Technosphere. It would disappoint me a great deal. Technosphere has been the reason I bought into MNKD. Don't get me wrong. I'm thrilled with Afrezza and its success in our lives, but I always figured inhalable technologies would revolutionize the industry. I just hope we only transferred of the rights to a few and not the whole shop..
|
|
|
Post by dreamboatcruise on Jan 21, 2016 10:26:53 GMT -5
What's interpretation on this bit? "MannKind will also transfer manufacturing technology to the licensee" Is this a transfer of TS IP? That doesn't sit well for nothing upfront + possible $100m down the road + possible ~10% sales down the road Can it be viewed as a spinoff of TS? Yes, they get TS technology, but what is in the PR implies that it is nonexclusive (MNKD still retains rights as well, and true ownership), and that the new partner hopefully only has for a limited number of API rather than the other way around where MNKD retains the rights to only a limited number of APIs. Need more details... and not I said "implies".
|
|
|
Post by jlaw277 on Jan 21, 2016 10:27:14 GMT -5
Single-digit/low double-digit royalty deals comprise the majority of biotech agreements today. MannKind would pay NONE of the development, production and eventual marketing expenses whatsoever. These deals can still be quite lucrative and there are plenty of examples in the market today. Pure speculation, but what could be very interesting would be if Viehbacher was somehow connected to the startup of RLS. The fact that RLS will be responsible for all development costs ties with the stated business strategy of Gurnet's first announced deal, Boston Pharmaceuticals. www.waypointcapital.net/newsThe assumption of development costs plus milestone payments in excess of $100 million seems to suggest that RLS is a well capitalized group. Viehbacher would obviously have intimate knowledge of MNKD's portfolio. At these levels, these assets would probably represent a "value" relative to a potential payout. www.fiercebiotech.com/story/chris-viehbacher-explains-if-i-had-2-billion-invest/2015-06-23-0www.genengnews.com/insight-and-intelligenceand153/top-10-u-s-biopharma-clusters/77900061/Once again, this is pure speculation while we still have no real news, but an investment from the Gurnet would add a very interesting twist to the rejection by Sanofi.
|
|
|
Post by bearcatmax on Jan 21, 2016 10:28:55 GMT -5
They said there would be CC before the earnings CC. Let's not over speculate here and try to wait until we hear what they have to say. If you read the social media this morning, opinions are all over the place. Pure speculation in all ways. Does no good.
|
|